321 related articles for article (PubMed ID: 15845923)
1. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
[TBL] [Abstract][Full Text] [Related]
2. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR
Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098
[TBL] [Abstract][Full Text] [Related]
3. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
4. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
5. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
7. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR
Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
[TBL] [Abstract][Full Text] [Related]
10. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
11. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
14. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
15. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
16. A synthetic glucagon-like peptide-1 analog with improved plasma stability.
Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G
J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346
[TBL] [Abstract][Full Text] [Related]
17. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
D'Alessio DA; Vogel R; Prigeon R; Laschansky E; Koerker D; Eng J; Ensinck JW
J Clin Invest; 1996 Jan; 97(1):133-8. PubMed ID: 8550824
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
[TBL] [Abstract][Full Text] [Related]
19. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
20. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
